Work

A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps3657

Authors: Apostolia Maria Tsimberidou, Jaffer A. Ajani, Pei Hsu, I-Ju Chen, Tillman E. Pearce

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Glycosylation and Glycoproteins Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3032212748

Cites:

Cited by: 3

Related to: 10